Related Experiment Videos
A study of the possible interactions between human platelets and the antibiotic MDL-507 (teicoplanin)
Abstract:
Teicoplanin, a new glycopeptide antibiotic, was tested for its ability to induce agglutination and/or aggregation of fresh and fixed human platelets in vitro. Two chemically related substances, ristocetin and vancomycin, were used as controls in the same experimental conditions, as they are known to be active and, respectively, nonactive on platelets. The studies with fresh platelet rich plasma (PRP) taken from 10 healthy volunteers and the studies with fixed washed platelets (FWP) were carried out at the final concentrations of teicoplanin and vancomycin of 10, 100, 2000 and 5000 mg/l. Unlike ristocetin, teicoplanin did not exhibit any agglutinating or aggregating activity, even when tested for concentrations 50 times as high as those measured in vivo during the peak time. At high concentrations it induced protein precipitation, albeit to a lesser extent than vancomycin.
Insights
Teicoplanin, a novel glycopeptide antibiotic, does not cause human platelet agglutination or aggregation in vitro. This finding is significant for understanding potential side effects of this important antibiotic.
Area of Science:
- Pharmacology
- Hematology
- Microbiology
Background:
- Teicoplanin is a novel glycopeptide antibiotic.
- Platelet function is crucial for hemostasis and thrombosis.
- Understanding drug interactions with platelets is vital for patient safety.
Purpose of the Study:
- To investigate the in vitro effects of teicoplanin on human platelet agglutination and aggregation.
- To compare teicoplanin's platelet activity with known agents like ristocetin and vancomycin.
Main Methods:
- Experiments were conducted using fresh platelet-rich plasma (PRP) and fixed washed platelets (FWP) from healthy volunteers.
- Teicoplanin and vancomycin were tested at various concentrations (10–5000 mg/l).
- Ristocetin served as a positive control for platelet aggregation.
Main Results:
- Teicoplanin demonstrated no agglutinating or aggregating activity on human platelets, even at high concentrations.
- Vancomycin, also a glycopeptide, showed minimal protein precipitation at high concentrations.
- Ristocetin, a known platelet aggregator, was used for comparison.
Conclusions:
- Teicoplanin does not appear to induce platelet agglutination or aggregation in vitro.
- This suggests a potentially favorable safety profile regarding platelet function for teicoplanin therapy.
- Further clinical studies may be warranted to confirm these in vitro findings.